Vaccines for poverty-related diseases

Under this call, large-scale collaborative projects are supported that include one or more clinical trials (phase I to IV) aiming to accelerate the clinical development of new vaccines (preventive or therapeutic) against one of the poverty-related infectious diseases. Applications included at least one clinical trial to be carried out in sub-Saharan Africa in order to test the safety, immunogenicity and/or efficacy of the vaccine(s).

MTBVAC in Newborns: Phase 2a dose-defining safety and immunogenicity study and capacity building to support vaccine efficacy trials in tuberculosis-endemic regions of sub-Saharan Africa

Biofabri S.L., Pontevedra, Spain with partners from Madagascar, Netherlands, Senegal, South Africa, Spain
Project coordinator: Ms. Ingrid Murillo, Biofabri S.L., Spain
Starting date: 1 January 2018
Duration: 36 months
Grant amount: EUR 5,537,093
Grant agreement: RIA2016V-1637

POR TB consortium: phase 2 trial to determine efficacy of the multistage vaccine H56:IC31 for prevention of recurrent TB disease

Statens Serum Institut (SSI), Copenhagen, Denmark with partners from Italy, South Africa, and Tanzania
Project coordinator: Prof. Peter L. Andersen, Statens Serum Institut, Copenhagen, Denmark
Starting date: 01 November 2017
Duration: 60 months
Grant amount: EUR 13,788,161
Grant agreement: RIA2016V-1631

A combination effect study in Africa of two DNA-MVA- or DNA- Env protein HIV-1 vaccine regimens with pre-exposure prophylaxis (PrEP)

Imperial Colloge of Science, Technology and Medicine (Imperial College), London, United Kingdom with partners from Germany, Sweden, Mozambique, South Africa, Switzerland, Tanzania, Uganda, United Kingdom, and United States
Project coordinator: Prof. Jonathan Weber, Imperial College, United Kingdom
Starting date: 1 January 2018
Duration: 63 months
Grant amount: EUR 14,999,955
Grant agreement: RIA2016V-1644